Media coverage about Cellect Biotechnology (NASDAQ:APOP) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cellect Biotechnology earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned news articles about the company an impact score of 49.9116014725759 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the media stories that may have effected Accern’s scoring:
Shares of Cellect Biotechnology traded up $0.23, reaching $7.23, during trading on Friday, Marketbeat reports. The company’s stock had a trading volume of 17,452 shares, compared to its average volume of 15,128. The stock has a market cap of $39.33 million, a PE ratio of -4.95 and a beta of 4.61. Cellect Biotechnology has a 52 week low of $6.12 and a 52 week high of $13.50.
Cellect Biotechnology (NASDAQ:APOP) last announced its earnings results on Thursday, May 17th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.14. equities analysts anticipate that Cellect Biotechnology will post -1.3 EPS for the current year.
Separately, Zacks Investment Research cut shares of Cellect Biotechnology from a “buy” rating to a “hold” rating in a research report on Monday, April 30th.
Cellect Biotechnology Company Profile
Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.
Receive News & Ratings for Cellect Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellect Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.